Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/81589
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.contributorSchool of Optometry-
dc.creatorZhou, Y-
dc.creatorChung, PY-
dc.creatorMa, JYW-
dc.creatorLam, AKY-
dc.creatorLaw, S-
dc.creatorChan, KW-
dc.creatorChan, ASC-
dc.creatorLi, X-
dc.creatorLam, KH-
dc.creatorChui, CH-
dc.creatorTang, JCO-
dc.date.accessioned2020-01-21T08:49:01Z-
dc.date.available2020-01-21T08:49:01Z-
dc.identifier.issn2079-7737en_US
dc.identifier.urihttp://hdl.handle.net/10397/81589-
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Zhou, Y., Chung, P. Y., Ma, J. Y. W., Lam, A. K. Y., Law, S., Chan, K. W., ... & Tang, J. C. O. (2019). Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells. Biology, 8(4), 75 is available at https://doi.org/10.3390/biology8040075en_US
dc.subjectAnticanceren_US
dc.subjectMultidrug resistanceen_US
dc.subjectP-glycoproteinen_US
dc.subjectQuinoline compoundsen_US
dc.titleDevelopment of a novel quinoline derivative as a P-glycoprotein inhibitor to reverse multidrug resistance in cancer cellsen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume8en_US
dc.identifier.issue4en_US
dc.identifier.doi10.3390/biology8040075en_US
dcterms.abstractMultidrug resistance (MDR) is one of conventional cancer chemotherapy’s limitations. Our group previously synthesized a series of quinoline-based compounds in an attempt to identify novel anticancer agents. With a molecular docking analysis, the novel compound 160a was predicted to target p-glycoprotein, an MDR candidate. The purpose of this study is to evaluate 160a’s MDR reversal effect and investigate the underlying mechanism at the molecular level. To investigate 160a’s inhibitory effect, we used a series of parental cancer cell lines (A549, LCC6, KYSE150, and MCF-7), the corresponding doxorubicin-resistant cell lines, an MTS cytotoxicity assay, an intracellular doxorubicin accumulation test, and multidrug resistance assays. The Compusyn program confirmed, with a combination index (CI) value greater than 1, that 160a combined with doxorubicin exerts a synergistic effect. Intracellular doxorubicin accumulation and transported calcein acetoxymethyl (AM) (a substrate for p-glycoprotein) were both increased when cancer cells with MDR were treated with compound 160a. We also showed that compound 160a’s MDR reversal effect can persist for at least 1 h. Taken together, these results suggest that the quinoline compound 160a possesses high potential to reverse MDR by inhibiting p-glycoprotein-mediated drug efflux in cancer cells with MDR.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationBiology, 2019, v. 8, no. 4, 75-
dcterms.isPartOfFire safety journal-
dcterms.issued2019-
dc.identifier.scopus2-s2.0-85073560105-
dc.identifier.eissn2079-7737en_US
dc.identifier.artn75en_US
dc.description.validate202001 bcmaen_US
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Zhou_Development_Novel_Quinoline.pdf4.3 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

49
Citations as of Jun 26, 2022

Downloads

51
Citations as of Jun 26, 2022

SCOPUSTM   
Citations

5
Citations as of Jun 23, 2022

WEB OF SCIENCETM
Citations

4
Citations as of Jun 23, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.